MedPath

Hoth Therapeutics' HT-001 Shows Promise in Treating EGFR Inhibitor-Induced Skin Toxicities

• Hoth Therapeutics' HT-001 demonstrated rapid improvement in papulopustular eruptions (PPEs), a common side effect of EGFR inhibitor therapy, in a patient with metastatic breast cancer. • The patient experienced significant symptom relief within one week of HT-001 treatment, leading to discontinuation of the therapy due to rapid healing of lesions. • Hoth has received IRB approval to proceed with a Phase IIa dose-ranging study of topical HT-001 for EGFR inhibitor-induced skin toxicities. • EGFR inhibitors often cause skin side effects, such as acneiform rashes, in up to 90% of patients, and HT-001 offers a potential solution for managing these toxicities.

Hoth Therapeutics has announced positive data from the treatment of the first patient with its lead candidate, HT-001, who was experiencing papulopustular eruptions (PPEs), a common and debilitating side effect of EGFR inhibitor (EGFRI) therapy in cancer patients. The 59-year-old female patient, undergoing treatment for metastatic breast cancer, witnessed significant improvement in symptoms just one week after receiving HT-001.

Rapid Symptom Relief with HT-001

Based on the rapid healing of lesions and relief of discomfort, the patient discontinued treatment after just one week. Notably, no new lesions appeared over the next three weeks, underscoring HT-001's potential as a safe and effective treatment for EGFRI-related PPEs. These results mark a significant milestone in addressing a serious unmet medical need experienced by cancer patients receiving EGFRI therapy. If successfully developed, the candidate could greatly improve the quality of life for cancer patients suffering from EGFRI-induced skin toxicities.

Addressing EGFR Inhibitor-Induced Skin Toxicities

EGFRIs, commonly used to treat various epithelial cancers, often cause skin side effects in the form of PPEs like acneiform rashes, affecting up to 90% of patients. These side effects, causing pruritus (itching) and burning, can be severe enough to disrupt or stop cancer treatments. HT-001 presents a new solution for managing these skin toxicities, providing quick symptom relief without interrupting the patient's ongoing cancer therapy.

Phase IIa Study to Evaluate HT-001

Hoth has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its first-in-human mid-stage study of topical HT-001 to treat EGFRI-induced skin toxicities. The ongoing phase IIa dose-ranging study will evaluate the efficacy, safety, and tolerability of HT-001 for this indication.

Hoth's Broader Pipeline

Beyond HT-001, Hoth is developing several other next-generation therapies for different unmet medical needs. One such investigational candidate is BioLexa, which is currently being developed in a separate early-stage study for the treatment of atopic dermatitis.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

SN Bioscience's SNB-101 Receives FDA Fast Track for Lung Cancer Treatment

SN Bioscience's SNB-101, a novel drug candidate, has been granted Fast Track designation by the FDA for the treatment of lung cancer.
The Fast Track designation aims to expedite the development and review of SNB-101, addressing an unmet need in lung cancer therapy.

Hoth Therapeutics' HT-001 Demonstrates 100% Success in Phase 2a Trial for Cancer Treatment Skin Toxicities

Hoth Therapeutics' HT-001 achieved a 100% success rate in a Phase 2a trial, significantly improving skin toxicities caused by EGFR inhibitors in cancer patients.
The CLEER-001 trial data showed that all patients achieved the primary efficacy endpoint, with notable improvements in skin toxicity by the six-week mark.

Citius Oncology Explores Strategic Options Post-Lymphir Approval for T-Cell Lymphoma

Citius Oncology is considering strategic alternatives, including partnerships and acquisitions, after FDA approval of Lymphir for relapsed or refractory cutaneous T-cell lymphoma (CTCL).
Lymphir, targeting the interleukin-2 (IL-2) receptor, is the first drug specifically for CTCL and aims to address an underserved market estimated at over $400 million.

Hemostemix Reports 83% Success Rate in Phase II Trial, Seeks OTCQB Up-listing

Hemostemix Inc. has announced plans to up-list to the OTCQB Venture Market while reporting significant clinical success with its ACP-01 therapy. Phase II trials showed 83% efficacy in treating peripheral arterial disease, with remarkable improvements in cardiac function and ulcer healing. The company aims to address a market of 236 million PAD patients worldwide.

Novel Compound SYM2081 Shows Promise in Treating Inflammatory Skin Conditions Like Rosacea

Researchers have identified a novel compound, SYM2081, that targets mast cells to reduce inflammation in skin conditions like rosacea.
Preclinical studies in mice and human cells demonstrated that SYM2081 effectively suppressed mast cell activity by activating glutamate receptors.

HOOKIPA Pharma's HB-200 Shows Promise in HPV16+ Head and Neck Cancer Treatment

HOOKIPA Pharma's HB-200 (eseba-vec) demonstrates encouraging results in clinical trials for HPV16-positive head and neck cancers, addressing a significant unmet medical need.
A pivotal Phase 2/3 trial (AVALON-1) is slated to begin in Q4 2024, evaluating HB-200 in combination with Keytruda for first-line treatment, with initial results expected in 2026.

HyBryte™ Shows Improved Response Rates in Cutaneous T-Cell Lymphoma with Extended Treatment

Soligenix's HyBryte™ (synthetic hypericin) demonstrates improved response rates in cutaneous T-cell lymphoma (CTCL) with extended treatment and increased light doses.
Presentations at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting highlight the utility of longer treatment times with HyBryte™.

Hoth Therapeutics Expands HT-001 Phase 2a Trial for EGFRi-Induced Skin Toxicities

Hoth Therapeutics has received IRB approval from Montefiore Medical Center and Dana-Farber Cancer Institute for its Phase 2a trial of HT-001.
The Phase 2a trial will assess the efficacy, safety, and tolerability of topical HT-001 for skin toxicities related to EGFR inhibitor treatments.

Hoth Therapeutics' HT-001 Shows Promise in Treating EGFRI-Associated Skin Toxicities

Hoth Therapeutics reports positive data from a human case study using HT-001 to treat EGFR inhibitor-associated papulopustular eruptions (PPEs).
A metastatic breast cancer patient experienced rapid symptom improvement after one week of HT-001 treatment, leading to treatment cessation.

Breakthroughs in Biotech: Promising Developments in Diabetes, Cancer, and Lymphoma Treatments

Recent advancements in the biotech sector highlight significant progress in treatments for diabetes, breast cancer, multiple myeloma, and T cell lymphoma, with several companies receiving FDA approvals or making notable strides in clinical trials.

Reference News

[1]
Hoth Stock Up as Lead Drug Heals Skin Toxicities in ...
finance.yahoo.com · Sep 6, 2024

Hoth Therapeutics' HT-001 showed promising results in treating papulopustular eruptions (PPEs) in a cancer patient, lead...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy